Key result
This review summarizes recent findings related to the pathophysiology and treatment of drug-induced cardiac dysfunction in cancer treatment.
This review summarizes recent findings on the pathophysiology and treatment of drug-induced cardiac dysfunction in cancer patients.
Synthesizes evolving cardio-oncology evidence; leaves open need for prospective trials to guide practice.
Treatment for cancer has improved in the last decades, resulting in a significantly reduced morbidity and mortality. 1-3 Unfortunately, many systemic treatment options are associated with an increased risk of adverse cardiac effects. 4 These adverse cardiac effects have given rise to the field of cardiooncology. This review summarizes recent findings related to the pathophysiology and treatment of drug-induced cardiac dysfunction in cancer treatment and looks ahead at new developments in the field.
No takes yet. Share an insight, caveat, or question.
Tromp et al. (2017) conducted a review in Drug-induced cardiac dysfunction in cancer treatment. This review summarizes recent findings related to the pathophysiology and treatment of drug-induced cardiac dysfunction in cancer treatment.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: